Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, recently hosted first of its kind series of Biopharma forums across India in Bengaluru, Hyderabad and Pune to emphasise Avantor’s commitment to creating customized solutions for customers by identifying and addressing the challenges faced by biopharma companies in India.

The Indian biopharmaceutical industry is rapidly expanding with increased investments in research and development, robust product pipelines, collaborations, and technological advancements. However, challenges such as constantly evolving regulatory compliances and price and quality control impede global competitiveness.

The 2024 Avantor Biopharma Forums focused on critical topics including scale-up, risk mitigation, and cost optimisation, which are crucial for addressing these challenges and driving growth in the biopharma industry.

With the goal of facilitating an enriching exchange of ideas for professionals within India’s Bioprocessing industry, the forums provided a platform for over 600 participants from some of the prominent biopharma players in India to engage with Avantor's products and solutions, fostering knowledge exchange and collaboration within the bioprocessing community.

The highlight of the forums was industry panel discussions with biopharma experts from leading biotechnology and biopharmaceutical companies across the three cities.

Ger Brophy, Chairman of Avantor’s Scientific Advisory Board, spoke about the Readiness for Changing Biological Molecules and Regulatory Environment and shared his perspective about the ever-evolving regulatory environment in the country.

Highlighting the evolution of the industry, Narayana Rao Rapolu, VP, Biopharma and Applied Products Solutions, said, “The Indian biopharma sector is witnessing a rise with the introduction of high-quality, cost-effective biosimilars into the market."

Nandkumar Deorkar, SVP Research and Development, Avantor, shared his insights about the effective management of Total Cost of Ownership in Bioprocessing. “At Avantor, we work to simplify our customers’ scale-up processes thereby eliminating process steps. Avantor’s objective is to create long- term, strategic partnerships within the industry by working closely with biomanufacturers to drive and foster cost optimisation and improve biologics process efficiencies."